Is Nkarta Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Nkarta Inc (NKTX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Nkarta Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Nkarta Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Nkarta Inc?

Muslim investors may consider investing in Nkarta Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Nkarta Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Nkarta Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Nkarta Inc updated?

The Shariah compliance status of Nkarta Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Nkarta Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Nkarta Inc?

You can check the latest Shariah compliance status of Nkarta Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NKTX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 01, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Nkarta Inc (NKTX)

Based on 13 analysts giving stock ratings to Nkarta Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Nkarta Inc. Stock Analysis NKTX

United States Health Care Micro Cap Report: 2025 Annual

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 108 full-time employees. The company went IPO on 2020-07-10. The firm is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

Key Statistics of Nkarta Inc (NKTX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$2.64$2.86

Today's Open

$2.82

Volume

730.25K

P/E Ratio (TTM)

52 Week Range

$1.63$3.65

Market Cap

219.57M

Avg. Volume

1.11M

Dividend Yield

Financial Metrics & Statements of Nkarta Inc (NKTX)

FAQ's for Nkarta Inc (NKTX)

According to Musaffa’s Shariah screening methodology, Nkarta Inc (NKTX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.